
    
      This will be a multi-center, open-label 40 week investigation in up to 1,200 men with signs
      and symptoms of benign prostatic hyperplasia. The following procedures are utilized: physical
      exams, electrocardiograms, clinical laboratory tests, vital signs, the International Prostate
      Symptom Score, maximum urine flow rate, adverse events, concomitant medications, and
      compliance.

      All subjects had previously participated in a 12-week double-blind placebo controlled trial
      (NCT000224107 or NCT000224120)
    
  